4Furchgott RF. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci Rep, 1999, 19 : 235-251.
5Furchgon RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288 : 373 -376.
6Gruetter CA, Gruetter DY, Lyon JE, et al. Relationship between cyclic guanosine 3' :5'-monophosphate formation and relaxation of coronary arterial smooth muscle by glyceryl trinitrate, nitroprusside, nitrite and nitric oxide: effects of methylene blue and methemoglobin. J Pharmacol Exp Ther, 1981,219 : 181 - 186.
7Ignarro LJ, Harbison RG, Wood KS, et al. Activation of purified soluble guanylate cyclase by endothelium-derived relaxing factor from intrapulmonary artery and vein: stimulation by acetylcholine, bradykinin and arachidonic acid. J Pharmacol Exp Ther, 1986, 237 : 893 -900.
8Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Nail Acad Sci USA, 1987, 84 :9265 -9269.
9Ignarro LJ, Byrns RE, Buga GM, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res, 1987, 61 : 866- 879.
10Murad F. Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci Rep, 1999, 19 : 133 - 154.
